rs3738919 — ITGAV ITGAV integrin alpha-V variant

ITGAV — When a Cell-Adhesion Receptor May Shape Arthritis Risk

Every joint in your body is partially sustained by a microscopic scaffolding of blood vessels. In rheumatoid arthritis, that scaffolding becomes a liability: new vessels grow into the synovial membrane¹¹ synovial membrane
The synovium is a thin membrane lining the joint cavity that produces lubricating fluid; in RA it becomes inflamed, thickened, and vascularized, forming the destructive "pannus" tissue that erodes cartilage and bone, feeding the invasion of immune cells and accelerating joint destruction. Integrin alpha-V, encoded by ITGAV on chromosome 2, is one of the key cell-surface receptors that controls this pathological vascular growth. The rs3738919 variant sits within an intron of ITGAV and may subtly alter how much of this receptor is expressed in synovial and immune cells — though the picture remains contested.

ITGAV encodes the alpha-V subunit that pairs with multiple beta partners (β1, β3, β5, β6, β8) to form integrin heterodimers. The best-characterized of these, integrin αvβ3²² integrin αvβ3
Also called the vitronectin receptor; binds RGD motifs in extracellular matrix proteins including fibronectin, vitronectin, and osteopontin; expressed on endothelial cells, osteoclasts, and activated macrophages, is a critical mediator of angiogenesis and is highly expressed on the new blood vessels that supply the RA synovium. Blocking αvβ3 reduces synovial vascular density in animal models, establishing a mechanistic rationale for investigating ITGAV genetic variants in RA.

The Mechanism

rs3738919 is an intronic variant in ITGAV (GRCh38 chr2:186,656,533, C>A substitution) with no direct protein-coding consequence. Located within an intron of the gene, it may function as a regulatory tag³³ regulatory tag
Intronic SNPs in strong linkage disequilibrium with nearby regulatory elements — enhancers, splice signals, transcription factor binding sites — can influence gene expression without altering the protein sequence for a haplotype affecting ITGAV transcriptional activity or mRNA processing in joint-resident or immune cells. No functional studies have directly measured whether the C or A allele at rs3738919 alters ITGAV expression levels in synovial tissue.

The biological rationale is strongest through the integrin αvβ3 angiogenesis axis. During RA, activated synovial fibroblasts and macrophages upregulate ITGAV-containing integrins to enable adhesion to the extracellular matrix, migration, and recruitment of additional inflammatory cells. If rs3738919 tags a variant that increases ITGAV expression, carriers of the C allele might mount a more robust vascular response to synovial inflammation — accelerating the pannus formation that drives joint erosion.

The Evidence

The original signal came from a family-based study⁴⁴ family-based study
Family-based designs use unaffected relatives as genetic controls, eliminating population stratification as a confound — a methodological strength for candidate gene studies in 100 French Caucasian RA trio families, replicated in 265 additional European families. The combined result showed the C allele was over-transmitted to affected offspring: OR 1.94 (95% CI 1.3–2.9, P=0.002). The accompanying editorial noted this finding "supports the role of angiogenesis in rheumatoid arthritis" as a genetically encoded susceptibility mechanism — one of the first family-based studies to implicate an angiogenesis gene in RA.

However, the larger replication effort substantially undermined this conclusion. A meta-analysis of four Caucasian cohorts⁵⁵ meta-analysis of four Caucasian cohorts
740 + 713 RA cases (NZ and Oxford) plus two independent replication cohorts, totaling 3,527 cases and 4,126 controls found no evidence of association (combined OR 0.92, 95% CI 0.80–1.07, P=0.29). A subsequent six-study meta-analysis⁶⁶ six-study meta-analysis
5,794 RA patients and 5,297 controls across studies in multiple ethnic populations confirmed that rs3738919 is not associated with RA risk in the overall population.

Notably, a related ITGAV variant — rs3768777⁷⁷ rs3768777
A different intronic polymorphism in the same gene, which showed OR 2.3 for RA in a Turkish cohort (P<0.0001) and OR 3.51 (P<0.0001) for Caucasians in the 2020 meta-analysis — has shown ethnicity-stratified association that rs3738919 lacks. This suggests rs3768777, not rs3738919, may be the functional or tagging variant at the ITGAV locus with clinical relevance for RA. The two variants may be in partial but imperfect linkage disequilibrium, explaining why initial studies positive for rs3738919 might have been capturing the rs3768777 signal.

Practical Actions

For individuals carrying one or two copies of the C allele at rs3738919, the evidence does not currently support a strong clinical intervention tied specifically to this variant. The contested replication means the C allele's RA risk status must be interpreted cautiously. Monitoring inflammatory biomarkers is reasonable for those with other RA risk factors (first-degree relatives with RA, carriage of shared epitope HLA alleles, positivity for ACPA or rheumatoid factor on clinical testing). The ITGAV-αvβ3 angiogenesis pathway does, however, offer a mechanistic rationale for dietary interventions that modulate synovial vascularity and integrin signaling.

Interactions

The strongest interaction context is the ITGAV locus itself. rs3768777 in the same gene has substantially stronger and better-replicated RA association evidence than rs3738919 and may represent the functionally relevant variant at this locus. Individuals carrying risk alleles at both rs3738919 and rs3768777 may have higher ITGAV-related susceptibility, though no combined study has formally evaluated this pairing. Beyond the ITGAV locus, integrin αvβ3 interacts with inflammatory cytokine pathways — TNF-alpha upregulates αvβ3 expression on synovial endothelium, suggesting that carriage of TNF-alpha pathway risk variants (e.g. rs1800629 in TNF) may compound synovial vascular risk in ITGAV C-allele carriers.